PHILADELPHIA – Scientists and clinicians from around the world will gather in Atlanta, Georgia next week at the American Association for Cancer Research’s second International Conference on Molecular Diagnostics in Cancer Therapeutic Development. The conference is subtitled “Maximizing Opportunities for Personalized Treatment,” which reflects the potential of molecular diagnostics to provide new strategies for tailoring therapies to fit the needs of each cancer patient’s unique biology.
Sessions will include discussions on the use of biomarkers – blood-borne molecules that indicate the presence of cancer – in clinical practice and new drug development, advanced imaging technologies for diagnosis, and the application of proteomics in personalized medicine. Novel findings to be reported at the conference include:
“As genetic, proteomic, imaging, and other new technologies become more sophisticated and our knowledge of tumor biology and signaling pathways advances, so too does our ability to molecularly characterize individual tumors and identify germline determinants of patient prognosis and response,” said David Sidransky, M.D., meeting chairperson and professor of Otolaryngology - Head and Neck Surgery, Oncology, Pathology, Urology, and Cellular and Molecular Medicine at Johns Hopkins University School of Medicine and director, Head and Neck Cancer Research at The Johns Hopkins Hospital.
“This new era of personalized medicine has brought with it great opportunities to enhance cancer drug development and improve patient care,” Dr. Sidransky said. “However, in order to harness this potential and maximize these opportunities, it is essential that there be an ongoing exchange of new ideas and information.”
In addition to symposia and poster sessions, the conference will include a keynote lecture by Victor E. Velculescu, M.D., Ph.D., assistant professor in the Department of Oncology at Johns Hopkins University’s Sidney Kimmel Comprehensive Cancer Center. Dr. Velculescu, a cancer genetics researcher, presents an address entitled “Blueprint of the Breast and Colorectal Cancer Genomes.”
The AACR’s second International Conference on Molecular Diagnostics in Cancer Therapeutic Development will be held Sept. 17 – 20, 2007, at the Atlanta Hilton. For press registration and more information about the conference, please visit http://www.aacr.org/home/scientists/meetings--workshops/molecular-diagnostics-in-cancer-therapeutic-development/press.aspx
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes nearly 26,000 basic, translational, and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 70 other countries.
AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants. The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field. Special Conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment, and patient care.
AACR publishes five major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Epidemiology, Biomarkers & Prevention. Its most recent publication, CR, is a magazine for cancer survivors, patient advocates, their families, physicians, and scientists. It provides a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship, and advocacy.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.